{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:10:49Z","timestamp":1790964649610,"version":"4.1.0"},"reference-count":119,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2020,10,9]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Neurological disorders are one of the major threat for health care system as they put enormous\nsocioeconomic burden. All aged populations are susceptible to one or other neurological problems\nwith symptoms of neuroinflammation, neurodegeneration and cognitive dysfunction. At present,\navailable pharmacotherapeutics are insufficient to treat these diseased conditions and in most cases,\nthey provide only palliative effect. It was also found that the molecular etiology of neurological disorders\nis directly linked with the alteration in genetic makeup, which can be inherited or triggered by the\ninjury, environmental toxins and by some existing disease. Therefore, to take care of this situation,\ngene therapy has emerged as an advanced modality that claims to permanently cure the disease by deletion,\nsilencing or edition of faulty genes and by insertion of healthier genes. In this modality, vectors\n(viral and non-viral) are used to deliver targeted gene into a specific region of the brain via various\nroutes. At present, gene therapy has shown positive outcomes in complex neurological disorders, such\nas Parkinson's disease, Alzheimer's disease, Huntington disease, Multiple sclerosis, Amyotrophic lateral\nsclerosis and in lysosomal storage disease. However, there are some limitations such as immunogenic\nreactions non-specificity of viral vectors and a lack of effective biomarkers to understand the efficacy\nof therapy. Considerable progress has been made to improve vector design, gene selection and\ntargeted delivery. This review article deals with the current status of gene therapy in neurological disorders\nalong with its clinical relevance, challenges and future prospective.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566523220999200716111502","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T06:29:37Z","timestamp":1594967377000},"page":"184-194","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Gene Therapy, A Novel Therapeutic Tool for Neurological Disorders: Current Progress, Challenges and Future Prospective"],"prefix":"10.2174","volume":"20","author":[{"given":"Ashif","family":"Iqubal","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi- 110062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Kashif","family":"Iqubal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi- 110062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamir","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi- 110062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi- 110062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjula","family":"Baboota","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi- 110062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2333-1577","authenticated-orcid":true,"given":"Syed Ehtaishamul","family":"Haque","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi- 110062, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/jnnp-2018-318297","volume":"90","author":"Keynejad R.C.","year":"2019","unstructured":"Keynejad R.C.; Frodl T.; Kanaan R.; Pariante C.; Reuber M.; Nicholson T.R.; Stress and functional neurological disorders: mechanistic insights. J Neurol Neurosurg Psychiatry 2019,90(7),813-821","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ana.24897","volume":"81","author":"Gooch C.L.","year":"2017","unstructured":"Gooch C.L.; Pracht E.; Borenstein A.R.; The burden of neurological disease in the United States: A summary report and call to action. Ann Neurol 2017,81(4),479-484","journal-title":"Ann Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMsa1204629","volume":"368","author":"Hurd M.D.","year":"2013","unstructured":"Hurd M.D.; Martorell P.; Delavande A.; Mullen K.J.; Langa K.M.; Monetary costs of dementia in the United States. N Engl J Med 2013,368(14),1326-1334","journal-title":"N Engl J Med"},{"key":"ref=4","doi-asserted-by":"publisher","author":"Patel V.","unstructured":"Patel V.; Chisholm D.; Dua T.; Laxminarayan R.;  Medina-M. Mental, neurological, and substance use disorders. In: disease control priorities, 3rd ed. Washington (DC): The World Bank; 2016; Vol 4","DOI":"10.1596\/978-1-4648-0426-7"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/TRD-160005","volume":"2","author":"Ferreira C.R.","year":"2017","unstructured":"Ferreira C.R.; Gahl W.A.; Lysosomal storage diseases. Transl Sci Rare Dis 2017,2(1-2),1-71","journal-title":"Transl Sci Rare Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","volume":"120","author":"Gribkoff V.K.","year":"2017","unstructured":"Gribkoff V.K.; Kaczmarek L.K.; The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology 2017,120,11-19","journal-title":"Neuropharmacology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.lfs.2018.09.025","volume":"211","author":"Iqubal A.","year":"2018","unstructured":"Iqubal A.; Sharma S.; Sharma K.; Intranasally administered pitavastatin ameliorates pentylenetetrazol-induced neuroinflammation, oxidative stress and cognitive dysfunction. Life Sci 2018,211,172-181","journal-title":"Life Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/1061186X.2019.1630415","volume":"28","author":"Pena S.A.","year":"2020","unstructured":"Pena S.A.; Iyengar R.; Eshraghi R.S.; Gene therapy for neurological disorders: challenges and recent advancements. J Drug Target 2020,28(2),111-128","journal-title":"J Drug Target"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2174\/1566523220666200107151025","volume":"19","author":"Tsagkaris C.","year":"2020","unstructured":"Tsagkaris C.; Papakosta V.; Miranda A.V.; Gene therapy for Angelman syndrome: Contemporary approaches and future endeavors. Curr Gene Ther 2020,19(6),359-366","journal-title":"Curr Gene Ther"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.01.015","author":"Chen W.","year":"2020","unstructured":"Chen W.; Hu Y.; Ju D.; Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharm Sin B 2020","journal-title":"Acta Pharm Sin B"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.1101\/720870","author":"Tiklov\u00e1 K.","year":"2019","unstructured":"Tiklov\u00e1 K.; Nolbrant S.; Fiorenzano A.; Bjorklund A.K.; Sharma Y.; Heuer A.; Single cell gene expression analysis reveals human stem cell-derived graft composition in a cell therapy model of Parkinson\u2019s disease. bioRxiv 2019","journal-title":"bioRxiv"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11481-016-9724-3","volume":"12","author":"Joshi C.R.","year":"2017","unstructured":"Joshi C.R.; Labhasetwar V.; Ghorpade A.; Destination brain: the past, present, and future of therapeutic gene delivery. J Neuroimmune Pharmacol 2017,12(1),51-83","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07882-8","volume":"10","author":"Zhong L.","year":"2019","unstructured":"Zhong L.; Xu Y.; Zhuo R.; Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer\u2019s disease model. Nat Commun 2019,10(1),1-6","journal-title":"Nat Commun"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00406-019-01019-8","volume":"269","author":"Schmitt A.","year":"2019","unstructured":"Schmitt A.; Simons M.; Cantuti-Castelvetri L.; Falkai P.; A new role for oligodendrocytes and myelination in schizophrenia and affective disorders? Eur Arch Psychiatry Clin Neurosci 2019,269(4),371-372","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2018.10.034","volume":"59","author":"Ahmad M.H.","year":"2019","unstructured":"Ahmad M.H.; Fatima M.; Mondal A.C.; Influence of microglia and astrocyte activation in the neuroinflammatory pathogenesis of Alzheimer\u2019s disease: Rational insights for the therapeutic approaches. J Clin Neurosci 2019,59,6-11","journal-title":"J Clin Neurosci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3233\/JAD-2008-13402","volume":"13","author":"Schwab C.","year":"2008","unstructured":"Schwab C.; McGeer P.L.; Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis 2008,13(4),359-369","journal-title":"J Alzheimers Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.brainresrev.2010.05.003","volume":"64","author":"Cardoso F.L.","year":"2010","unstructured":"Cardoso F.L.; Brites D.; Brito M.A.; Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Brain Res Rev 2010,64(2),328-363","journal-title":"Brain Res Brain Res Rev"},{"key":"ref=18","doi-asserted-by":"publisher","author":"Pandit R","unstructured":"Pandit R; Chen L; G\u00f6tz J.;  The blood-brain barrier: Physiology and strategies for drug delivery. Adv Drug Deliv Rev 2019; S0169- 409X(19): 30238-8.","DOI":"10.1016\/j.addr.2019.11.009"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"Abbott N.J.","year":"2010","unstructured":"Abbott N.J.; Patabendige A.A.; Dolman D.E.; Yusof S.R.; Begley D.J.; Structure and function of the blood-brain barrier. Neurobiol Dis 2010,37(1),13-25","journal-title":"Neurobiol Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s13311-014-0299-5","volume":"11","author":"Maguire C.A.","year":"2014","unstructured":"Maguire C.A.; Ramirez S.H.; Merkel S.F.; Sena-Esteves M.; Breakefield X.O.; Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics 2014,11(4),817-839","journal-title":"Neurotherapeutics"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.brainresbull.2019.05.024","volume":"150","author":"Puhl D.L.","year":"2019","unstructured":"Puhl D.L.; D\u2019Amato A.R.; Gilbert R.J.; Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors. Brain Res Bull 2019,150,216-230","journal-title":"Brain Res Bull"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/mt.2009.71","volume":"17","author":"Duque S.","year":"2009","unstructured":"Duque S.; Joussemet B.; Riviere C.; Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009,17(7),1187-1196","journal-title":"Mol Ther"},{"key":"ref=23","first-page":"143","author":"Gessler D.J.","year":"2019","unstructured":"Gessler D.J.; Tai P.W.; Li J.; Gao G.;  Intravenous infusion of AAV for widespread gene delivery to the nervous system in adeno-associated virus vectors 2019,143-163","journal-title":"Intravenous infusion of AAV for widespread gene delivery to the nervous system in adeno-associated virus vectors"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/nano9010105","volume":"9","author":"Caffery B.","year":"2019","unstructured":"Caffery B.; Lee J.S.; Alexander-Bryant A.A.; Vectors for glioblastoma gene therapy: viral","journal-title":"Nanomaterials (Basel)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"Hudry E.","year":"2019","unstructured":"Hudry E.; Vandenberghe L.H.; Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 2019,101(5),839-862","journal-title":"Neuron"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1523\/JNEUROSCI.6439-11.2012","volume":"32","author":"Hudry E.","year":"2012","unstructured":"Hudry E.; Wu H.Y.; Arbel-Ornath M.; Inhibition of the NFAT pathway alleviates amyloid \u03b2 neurotoxicity in a mouse model of Alzheimer\u2019s disease. J Neurosci 2012,32(9),3176-3192","journal-title":"J Neurosci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/mt.2013.169","volume":"21","author":"Quintino L.","year":"2013","unstructured":"Quintino L.; Manfr\u00e9 G.; Wettergren E.E.; Namislo A.; Isaksson C.; Lundberg C.; Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson\u2019s disease. Mol Ther 2013,21(12),2169-2180","journal-title":"Mol Ther"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1126\/science.290.5492.767","volume":"290","author":"Kordower J.H.","year":"2000","unstructured":"Kordower J.H.; Emborg M.E.; Bloch J.; Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson\u2019s disease. Science 2000,290(5492),767-773","journal-title":"Science"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/mt.2009.44","volume":"17","author":"Kiyota T.","year":"2009","unstructured":"Kiyota T.; Yamamoto M.; Schroder B.; AAV1\/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, \u03b2-amyloidosis, and learning impairment of APP\/PS1 mice. Mol Ther 2009,17(5),803-809","journal-title":"Mol Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","volume":"13","author":"Spronck E.A.","year":"2019","unstructured":"Spronck E.A.; Brouwers C.C.; Vall\u00e8s A.; AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in huntington disease mouse models. Mol Ther Methods Clin Dev 2019,13,334-343","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1089\/hum.2016.171","volume":"28","author":"Valdmanis P.N.","year":"2017","unstructured":"Valdmanis P.N.; Kay M.A.; Future of rAAV gene therapy: platform for RNAi, gene editing, and beyond. Hum Gene Ther 2017,28(4),361-372","journal-title":"Hum Gene Ther"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006227","volume":"4","author":"Desclaux M.","year":"2009","unstructured":"Desclaux M.; Teigell M.; Amar L.; A novel and efficient gene transfer strategy reduces glial reactivity and improves neuronal survival and axonal growth in vitro. PLoS One 2009,4(7)","journal-title":"PLoS One"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1096\/fj.02-1183fje","volume":"17","author":"Nicchia G.P.","year":"2003","unstructured":"Nicchia G.P.; Frigeri A.; Liuzzi G.M.; Svelto M.; Inhibition of aquaporin-4 expression in astrocytes by RNAi determines alteration in cell morphology, growth, and water transport and induces changes in ischemia-related genes. FASEB J 2003,17(11),1508-1510","journal-title":"FASEB J"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41593-019-0352-0","volume":"22","author":"Park H.","year":"2019","unstructured":"Park H.; Oh J.; Shim G.; In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer\u2019s disease. Nat Neurosci 2019,22(4),524-528","journal-title":"Nat Neurosci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/mds.26020","volume":"29","author":"Aronin N.","year":"2014","unstructured":"Aronin N.; DiFiglia M.; Huntingtin-lowering strategies in Huntington\u2019s disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord 2014,29(11),1455-1461","journal-title":"Mov Disord"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"11461","DOI":"10.1073\/pnas.1405186111","volume":"111","author":"Hu W.","year":"2014","unstructured":"Hu W.; Kaminski R.; Yang F.; RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA 2014,111(31),11461-11466","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.semperi.2018.09.003","volume":"42","author":"Memi F.","year":"2018","unstructured":"Memi F.; Ntokou A.; Papangeli I.; CRISPR\/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations. Seminars in perinatology 2018,42(8),487-500","journal-title":"Seminars in perinatology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4155\/tde-2019-0076","volume":"11","author":"Redd Bowman K.E.","year":"2020","unstructured":"Redd Bowman K.E.; Lu P.; Vander Mause E.R.; Lim C.S.; Advances in delivery vectors for gene therapy in liver cancer. Ther Deliv 2020,11(1),833-850","journal-title":"Ther Deliv"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrneurol.2016.190","volume":"13","author":"McMahon M.A.","year":"2017","unstructured":"McMahon M.A.; Cleveland D.; Gene therapy: gene-editing therapy for neurological disease. Nat Rev Neurol 2017,13(1),7","journal-title":"Nat Rev Neurol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"Li C.","year":"2020","unstructured":"Li C.; Samulski R.J.; Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet 2020,21(4),255-272","journal-title":"Nat Rev Genet"},{"key":"ref=41","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9065-8","author":"Manfredsson F.P.","year":"2019","unstructured":"Manfredsson F.P.; Benskey M.J.;  Viral vectors for gene therapy: methods and protocols 2019","journal-title":"Viral vectors for gene therapy: methods and protocols"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/1535676019899502","volume":"25","author":"Ghosh S.","year":"2020","unstructured":"Ghosh S.; Brown A.M.; Jenkins C.; Campbell K.; Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges. Appl Biosaf 2020,25(1),7-18","journal-title":"Appl Biosaf"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"Kaplitt M.G.","year":"2007","unstructured":"Kaplitt M.G.; Feigin A.; Tang C.; Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet 2007,369(9579),2097-2105","journal-title":"Lancet"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"Naso M.F.","year":"2017","unstructured":"Naso M.F.; Tomkowicz B.; Perry W.L.; Strohl W.R.; Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 2017,31(4),317-334","journal-title":"BioDrugs"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"Colella P.","year":"2017","unstructured":"Colella P.; Ronzitti G.; Mingozzi F.; Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev 2017,8,87-104","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"Mendell J.R.","year":"2017","unstructured":"Mendell J.R.; Al-Zaidy S.; Shell R.; Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017,377(18),1713-1722","journal-title":"N Engl J Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/hum.2013.200","volume":"25","author":"Stanek L.M.","year":"2014","unstructured":"Stanek L.M.; Sardi S.P.; Mastis B.; Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease. Hum Gene Ther 2014,25(5),461-474","journal-title":"Hum Gene Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/mt.2009.17","volume":"17","author":"Boudreau R.L.","year":"2009","unstructured":"Boudreau R.L.; McBride J.L.; Martins I.; Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice. Mol Ther 2009,17(6),1053-1063","journal-title":"Mol Ther"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-4939-9814-2_4","author":"Goins W.F.","year":"2020","unstructured":"Goins W.F.; Huang S.; Hall B.; Marzulli M.; Cohen J.B.; Glorioso J.C.; Engineering HSV-1 vectors for gene therapy. Herpes Simplex Virus 2020,73-90","journal-title":"Herpes Simplex Virus"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/hum.2016.007","volume":"27","author":"Negre O.","year":"2016","unstructured":"Negre O.; Eggimann A.V.; Beuzard Y.; Gene therapy of the \u03b2-hemoglobinopathies by lentiviral transfer of the \u03b2A (T87Q)-Globin gene. Hum Gene Ther 2016,27(2),148-165","journal-title":"Hum Gene Ther"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2174\/1566523217666171003170348","volume":"17","author":"Kalesnykas G.","year":"2017","unstructured":"Kalesnykas G.; Kokki E.; Alasaarela L.; Comparative study of adeno-associated virus, adenovirus, bacu lovirus and lentivirus vectors for gene therapy of the eyes. Curr Gene Ther 2017,17(3),235-247","journal-title":"Curr Gene Ther"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13041-018-0348-9","volume":"11","author":"Tan V.T.Y.","year":"2018","unstructured":"Tan V.T.Y.; Mockett B.G.; Ohline S.M.; Lentivirus-mediated expression of human secreted amyloid precursor protein-alpha prevents development of memory and plasticity deficits in a mouse model of Alzheimer\u2019s disease. Mol Brain 2018,11(1),7","journal-title":"Mol Brain"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"Mingozzi F.","year":"2013","unstructured":"Mingozzi F.; High K.A.; Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013,122(1),23-36","journal-title":"Blood"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2019.102115","volume":"23","author":"Choi J.","year":"2020","unstructured":"Choi J.; Rui Y.; Kim J.; Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies. Nanomedicine (Lond) 2020,23","journal-title":"Nanomedicine (Lond)"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1566523217666170605115829","volume":"17","author":"Eslaminejad T.","year":"2017","unstructured":"Eslaminejad T.; Nematollahi-Mahani S.N.; Ansari M.; Glioblastoma targeted gene therapy based on pEGFP\/p53-loaded superparamagnetic iron oxide nanoparticles. Curr Gene Ther 2017,17(1),59-69","journal-title":"Curr Gene Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/pharmaceutics12010039","volume":"12","author":"Osipova O.","year":"2020","unstructured":"Osipova O.; Sharoyko V.; Zashikhina N.; Amphiphilic polypeptides for VEGF siRNA delivery into retinal epithelial cells. Pharmaceutics 2020,12(1),39","journal-title":"Pharmaceutics"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1080\/17425247.2016.1188802","volume":"13","author":"Jayant R.D.","year":"2016","unstructured":"Jayant R.D.; Sosa D.; Kaushik A.; Current status of non-viral gene therapy for CNS disorders. Expert Opin Drug Deliv 2016,13(10),1433-1445","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=58","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfa.2019.124054","volume":"58","author":"Zhang C.","year":"2020","unstructured":"Zhang C.; Zhang S.; Zhi D.; Zhao Y.; Cui S.; Cui J.; Co-delivery of paclitaxel and survivin siRNA with cationic liposome for lung cancer therapy. Colloids Surf 2020,58","journal-title":"Colloids Surf"},{"key":"ref=59","doi-asserted-by":"publisher","author":"Suk JS","unstructured":"Suk JS; Xu Q; Kim N; Hanes J; Ensign LM;  PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.. Adv Drug Deliv Rev 2016; 99(Pt A): 28-51.","DOI":"10.1016\/j.addr.2015.09.012"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/gt.2011.130","volume":"19","author":"Federici T.","year":"2012","unstructured":"Federici T.; Taub J.S.; Baum G.R.; Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther 2012,19(8),852-859","journal-title":"Gene Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41598-017-01004-y","volume":"7","author":"Dang C.H.","year":"2017","unstructured":"Dang C.H.; Aubert M.; De Silva Feelixge H.S.; In vivo dynamics of AAV-mediated gene delivery to sensory neurons of the trigeminal ganglia. Sci Rep 2017,7(1),927","journal-title":"Sci Rep"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","volume":"70","author":"Eberling J.L.","year":"2008","unstructured":"Eberling J.L.; Jagust W.J.; Christine C.W.; Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008,70(21),1980-1983","journal-title":"Neurology"},{"key":"ref=63","volume":"20","author":"Kunwar S.","year":"2006","unstructured":"Kunwar S.; Chang S.M.; Prados M.D.; Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 2006,20(4)","journal-title":"Neurosurg Focus"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2011.220","volume":"23","author":"Mittermeyer G.","year":"2012","unstructured":"Mittermeyer G.; Christine C.W.; Rosenbluth K.H.; Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson\u2019s disease. Hum Gene Ther 2012,23(4),377-381","journal-title":"Hum Gene Ther"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"Foust K.D.","year":"2009","unstructured":"Foust K.D.; Nurre E.; Montgomery C.L.; Hernandez A.; Chan C.M.; Kaspar B.K.; Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009,27(1),59-65","journal-title":"Nat Biotechnol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrd.2018.110","volume":"17","author":"Deverman B.E.","year":"2018","unstructured":"Deverman B.E.; Ravina B.M.; Bankiewicz K.S.; Paul S.M.; Sah D.W.Y.; Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov 2018,17(9),641-659","journal-title":"Nat Rev Drug Discov"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","volume":"16","author":"Sudhakar V.","year":"2019","unstructured":"Sudhakar V.; Richardson R.M.; Gene therapy for neurodegenerative diseases. Neurotherapeutics 2019,16(1),166-175","journal-title":"Neurotherapeutics"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41583-019-0257-7","volume":"21","author":"Parmar M.","year":"2020","unstructured":"Parmar M.; Grealish S.; Henchcliffe C.; The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci 2020,21(2),103-115","journal-title":"Nat Rev Neurosci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1056\/NEJM199810153391607","volume":"339","author":"Lang A.E.","year":"1998","unstructured":"Lang A.E.; Lozano A.M.; Parkinson\u2019s disease. Second of two parts. N Engl J Med 1998,339(16),1130-1143","journal-title":"N Engl J Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2ra4","DOI":"10.1126\/scitranslmed.3000130","volume":"1","author":"Jarraya B.","year":"2009","unstructured":"Jarraya B.; Boulet S.; Ralph G.S.; Dopamine gene therapy for Parkinson\u2019s disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 2009,1(2),2ra4","journal-title":"Sci Transl Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/00001756-200404290-00011","volume":"15","author":"Azzouz M.","year":"2004","unstructured":"Azzouz M.; Ralph S.; Wong L-F.; Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector. Neuroreport 2004,15(6),985-990","journal-title":"Neuroreport"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"10302","DOI":"10.1523\/JNEUROSCI.22-23-10302.2002","volume":"22","author":"Azzouz M.","year":"2002","unstructured":"Azzouz M.; Martin-Rendon E.; Barber R.D.; Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson\u2019s disease. J Neurosci 2002,22(23),10302-10312","journal-title":"J Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/mt.2010.135","volume":"18","author":"Muramatsu S.","year":"2010","unstructured":"Muramatsu S.; Fujimoto K.; Kato S.; A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson\u2019s disease. Mol Ther 2010,18(9),1731-1735","journal-title":"Mol Ther"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1089\/hum.2019.359","volume":"31","author":"Kanao-Kanda M.","year":"2020","unstructured":"Kanao-Kanda M.; Kanda H.; Liu S.; Roy S.; Toborek M.; Hao S.; Viral vector-mediated gene transfer of glutamic acid decarboxylase for chronic pain treatment: a literature review. Hum Gene Ther 2020,31(7-8),405-414","journal-title":"Hum Gene Ther"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3390\/ijms21020590","volume":"21","author":"Mu\u00f1oz M.D.","year":"2020","unstructured":"Mu\u00f1oz M.D.; de la Fuente N.; S\u00e1nchez-Capelo A.; TGF-\u03b2\/Smad3 signalling modulates GABA neurotransmission: Implications in Parkinson\u2019s disease. Int J Mol Sci 2020,21(2),590","journal-title":"Int J Mol Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"LeWitt P.A.","year":"2011","unstructured":"LeWitt P.A.; Rezai A.R.; Leehey M.A.; AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011,10(4),309-319","journal-title":"Lancet Neurol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"Marks W.J.","year":"2010","unstructured":"Marks W.J.; Bartus R.T.; Siffert J.; Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010,9(12),1164-1172","journal-title":"Lancet Neurol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2217\/fon-2018-0719","volume":"15","author":"Shu C.","year":"2019","unstructured":"Shu C.; Yan X.; Zhang X.; Wang Q.; Cao S.; Wang J.; Tumor-induced mortality in adult primary supratentorial glioblastoma multiforme with different age subgroups. Future Oncol 2019,15(10),1105-1114","journal-title":"Future Oncol"},{"key":"ref=79","first-page":"491","volume":"3","author":"Izquierdo M.","year":"1996","unstructured":"Izquierdo M.; Mart\u00edn V.; de Felipe P.; Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)\/ganciclovir gene therapy. Gene Ther 1996,3(6),491-495","journal-title":"Gene Ther"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.ymthe.2004.08.002","volume":"10","author":"Immonen A.","year":"2004","unstructured":"Immonen A.; Vapalahti M.; Tyynel\u00e4 K.; AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004,10(5),967-972","journal-title":"Mol Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1200\/JCO.2003.21.13.2508","volume":"21","author":"Lang F.F.","year":"2003","unstructured":"Lang F.F.; Bruner J.M.; Fuller G.N.; Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003,21(13),2508-2518","journal-title":"J Clin Oncol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jocn.2011.12.016","volume":"19","author":"Yun J.","year":"2012","unstructured":"Yun J.; Sonabend A.M.; Ulasov I.V.; A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery. J Clin Neurosci 2012,19(6),875-880","journal-title":"J Clin Neurosci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/14740338.2020.1713089","volume":"19","author":"Li J.","year":"2020","unstructured":"Li J.; Sun M.; Wang X.; The adverse-effect profile of lacosamide. Expert Opin Drug Saf 2020,19(2),131-138","journal-title":"Expert Opin Drug Saf"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"7191","DOI":"10.1073\/pnas.0810710106","volume":"106","author":"Paradiso B.","year":"2009","unstructured":"Paradiso B.; Marconi P.; Zucchini S.; Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci USA 2009,106(17),7191-7196","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=85","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004190","volume":"4","author":"Wykes R.C.","year":"2012","unstructured":"Wykes R.C.; Heeroma J.H.; Mantoan L.; Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci Transl Med 2012,4(161)","journal-title":"Sci Transl Med"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1523\/JNEUROSCI.1143-18.2019","volume":"39","author":"Snowball A.","year":"2019","unstructured":"Snowball A.; Chabrol E.; Wykes R.C.; Epilepsy gene therapy using an engineered potassium channel. J Neurosci 2019,39(16),3159-3169","journal-title":"J Neurosci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/brain\/awn079","volume":"131","author":"No\u00e8 F.","year":"2008","unstructured":"No\u00e8 F.; Pool A.H.; Nissinen J.; Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008,131(Pt 6),1506-1515","journal-title":"Brain"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/gt.2010.23","volume":"17","author":"Noe F.","year":"2010","unstructured":"Noe F.; Vaghi V.; Balducci C.; Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. Gene Ther 2010,17(5),643-652","journal-title":"Gene Ther"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.yebeh.2019.04.042","volume":"97","author":"Mesraoua B.","year":"2019","unstructured":"Mesraoua B.; Deleu D.; Kullmann D.M.; Novel therapies for epilepsy in the pipeline. Epilepsy Behav 2019,97,282-290","journal-title":"Epilepsy Behav"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.brainresbull.2018.11.008","volume":"151","author":"Weltha L.","year":"2019","unstructured":"Weltha L.; Reemmer J.; Boison D.; The role of adenosine in epilepsy. Brain Res Bull 2019,151,46-54","journal-title":"Brain Res Bull"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1528-1167.2010.02947.x","volume":"52","author":"Theofilas P.","year":"2011","unstructured":"Theofilas P.; Brar S.; Stewart K.A.; Adenosine kinase as a target for therapeutic antisense strategies in epilepsy. Epilepsia 2011,52(3),589-601","journal-title":"Epilepsia"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2174\/1389450119666191014104347","volume":"21","author":"Wang X.","year":"2020","unstructured":"Wang X.; Li T.; Role of adenosine kinase inhibitor in adenosine augmentation therapy for epilepsy: a potential novel drug for epilepsy. Curr Drug Targets 2020,21(3),252-257","journal-title":"Curr Drug Targets"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1001\/jamaneurol.2019.4962","volume":"77","author":"Jack C.R.","year":"2020","unstructured":"Jack C.R.; Alzheimer Disease, Biomarkers, and Clinical Symptoms-Quo Vadis?-Reply. JAMA Neurol 2020,77(3),394","journal-title":"JAMA Neurol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/07315724.2019.1683379","volume":"39","author":"Agnihotri A.","year":"2020","unstructured":"Agnihotri A.; Aruoma O.I.; Alzheimer\u2019s disease and Parkinson\u2019s disease: A nutritional toxicology perspective of the impact of oxidative stress, mitochondrial dysfunction, nutrigenomics and environmental chemicals. J Am Coll Nutr 2020,39(1),16-27","journal-title":"J Am Coll Nutr"},{"key":"ref=95","author":"Libon D.J.","unstructured":"Libon D.J.; Lamar M.; Swenson R.A.; Heilman K.M.;  Vascular disease, Alzheimer's disease, and mild cognitive impairment: advancing an integrated approach. Oxford University Press 2020; 9(1): pp. 76-92."},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fnins.2019.00533","volume":"13","author":"Mufson E.J.","year":"2019","unstructured":"Mufson E.J.; Counts S.E.; Ginsberg S.D.; Nerve growth factor pathobiology during the progression of Alzheimer\u2019s disease. Front Neurosci 2019,13,533-544","journal-title":"Front Neurosci"},{"key":"ref=97","first-page":"1413","volume":"44","author":"Huang Z.","year":"2019","unstructured":"Huang Z.; Li J.; Zhou J.; Zhang J.; Alzheimer\u2019s disease and nerve growth factor gene therapy. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2019,44(12),1413-1418","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.wneu.2018.09.097","volume":"121","author":"Hitti F.L.","year":"2019","unstructured":"Hitti F.L.; Gonzalez-Alegre P.; Lucas T.H.; Gene therapy for neurologic disease: a neurosurgical review. World Neurosurg 2019,121,261-273","journal-title":"World Neurosurg"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"931","DOI":"10.4103\/1673-5374.250570","volume":"14","author":"Qu Y.","year":"2019","unstructured":"Qu Y.; Liu Y.; Noor A.F.; Tran J.; Li R.; Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases. Neural Regen Res 2019,14(6),931-938","journal-title":"Neural Regen Res"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.omtm.2019.12.012","volume":"17","author":"Li Y.","year":"2020","unstructured":"Li Y.; Wang Y.; Wang J.; Expression of neprilysin in skeletal muscle by ultrasound-mediated gene transfer (Sonoporation) reduces amyloid burden for AD. Mol Ther Methods Clin Dev 2020,17,300-308","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/sj.gt.3302719","volume":"13","author":"Hong C.S.","year":"2006","unstructured":"Hong C.S.; Goins W.F.; Goss J.R.; Burton E.A.; Glorioso J.C.; Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer\u2019s disease-related amyloid-\u03b2 peptide in vivo. Gene Ther 2006,13(14),1068-1079","journal-title":"Gene Ther"},{"key":"ref=102","first-page":"240","volume":"12","author":"Mandel R.J.","year":"2010","unstructured":"Mandel R.J.; CERE-110, An adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer\u2019s disease. Curr Opin Mol Ther 2010,12(2),240-247","journal-title":"Curr Opin Mol Ther"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"13966","DOI":"10.1523\/JNEUROSCI.3637-10.2010","volume":"30","author":"Piedrahita D.","year":"2010","unstructured":"Piedrahita D.; Hern\u00e1ndez I.; L\u00f3pez-Tob\u00f3n A.; Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer\u2019s mice. J Neurosci 2010,30(42),13966-13976","journal-title":"J Neurosci"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3233\/JAD-190026","volume":"71","author":"Quan Q.","year":"2019","unstructured":"Quan Q.; Qian Y.; Li X.; Li M.; CDK5 participates in amyloid-\u03b2 production by regulating PPAR\u03b3 phosphorylation in primary rat hippocampal neurons. J Alzheimers Dis 2019,71(2),443-460","journal-title":"J Alzheimers Dis"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/978-1-4939-9465-6_9","author":"Jain K.K.","year":"2019","unstructured":"Jain K.K.;  Neuroprotection in huntington disease the handbook of neuroprotection 2019,587-607","journal-title":"Neuroprotection in huntington disease the handbook of neuroprotection"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.expneurol.2003.09.002","volume":"185","author":"Zala D.","year":"2004","unstructured":"Zala D.; Bensadoun J.C.; Pereira de Almeida L.; Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington\u2019s disease transgenic mice. Exp Neurol 2004,185(1),26-35","journal-title":"Exp Neurol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mcn.2019.01.006","volume":"95","author":"Colpo G.D.","year":"2019","unstructured":"Colpo G.D.; Furr Stimming E.; Teixeira A.L.; Stem cells in animal models of Huntington disease: A systematic review. Mol Cell Neurosci 2019,95,43-50","journal-title":"Mol Cell Neurosci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40263-019-00695-3","volume":"34","author":"Shannon K.M.","year":"2020","unstructured":"Shannon K.M.; Recent advances in the treatment of Huntington\u2019s disease: Targeting DNA and RNA. CNS Drugs 2020,34(3),219-228","journal-title":"CNS Drugs"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"A78","DOI":"10.1089\/hgtb.2016.149","volume":"28","author":"Spronck E.A.","year":"2017","unstructured":"Spronck E.A.; Valles-Sanchez A.; Heikkinen T.; AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models. Hum Gene Ther 2017,28,A78","journal-title":"Hum Gene Ther"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"53","DOI":"10.23838\/pfm.2018.00037","volume":"2","author":"Hwang J.Y.","year":"2018","unstructured":"Hwang J.Y.; Won J.S.; Nam H.; Lee H.W.; Joo K.M.; Current advances in combining stem cell and gene therapy for neurodegenerative diseases. Precis Future Med 2018,2(2),53-65","journal-title":"Precis Future Med"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40035-017-0101-9","volume":"6","author":"Aguiar S.","year":"2017","unstructured":"Aguiar S.; van der Gaag B.; Cortese F.A.B.; RNAi mechanisms in Huntington\u2019s disease therapy: siRNA versus shRNA. Transl Neurodegener 2017,6(1),30","journal-title":"Transl Neurodegener"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/sj.gt.3303048","volume":"15","author":"Shen F.","year":"2008","unstructured":"Shen F.; Fan Y.; Su H.; Adeno-associated viral vector-mediated hypoxia-regulated VEGF gene transfer promotes angiogenesis following focal cerebral ischemia in mice. Gene Ther 2008,15(1),30-39","journal-title":"Gene Ther"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"Ross C.A.","year":"2014","unstructured":"Ross C.A.; Aylward E.H.; Wild E.J.; Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014,10(4),204-216","journal-title":"Nat Rev Neurol"},{"key":"ref=114","first-page":"9","volume":"8","author":"Deviatkin A.A.","year":"2020","unstructured":"Deviatkin A.A.; Vakulenko Y.A.; Akhmadishina L.V.; Emerging concepts and challenges in rheumatoid arthritis. Gen Ther 2020,8(1),9","journal-title":"Gen Ther"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ymthe.2017.03.018","volume":"25","author":"Thrasher A.J.","year":"2017","unstructured":"Thrasher A.J.; Williams D.A.; Evolving gene therapy in primary immunodeficiency. Mol Ther 2017,25(5),1132-1141","journal-title":"Mol Ther"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.omtm.2017.04.006","volume":"5","author":"Sinnett S.E.","year":"2017","unstructured":"Sinnett S.E.; Hector R.D.; Gadalla K.K.E.; Improved MECP2 gene therapy extends the survival of MeCP2-null mice without apparent toxicity after intracisternal delivery. Mol Ther Methods Clin Dev 2017,5,106-115","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"GE01","DOI":"10.7860\/JCDR\/2015\/10443.5394","volume":"9","author":"Ramamoorth M.","year":"2015","unstructured":"Ramamoorth M.; Narvekar A.; Non viral vectors in gene therapy- an overview. J Clin Diagn Res 2015,9(1),GE01-GE06","journal-title":"J Clin Diagn Res"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"51","DOI":"10.18609\/cgti.2019.007","volume":"5","author":"Nyamay\u2019Antu A.","year":"2019","unstructured":"Nyamay\u2019Antu A.; Dumont M.; Kedinger V.; Erbacher P.; Non-viral vector mediated gene delivery: the outsider to watch out for in gene therapy. Cell Gene Ther Insights 2019,5,51-57","journal-title":"Cell Gene Ther Insights"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/156652312800099580","volume":"12","author":"Humbert J.M.","year":"2012","unstructured":"Humbert J.M.; Halary F.; Viral and non-viral methods to genetically modify dendritic cells. Curr Gene Ther 2012,12(2),127-136","journal-title":"Curr Gene Ther"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/183795","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183795\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/183795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T20:11:15Z","timestamp":1614456675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183795\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":119,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,10,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523220999200716111502","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}